Technology developed by a consortium of eight European partners under a €2.1 million grant from the European Commission's Information Society Technologies Programme has been tested to measure the effects of medical implants on blood flow. The system, which will be available for licence in the future, aims to help medical device makers improve the design of heart valves and pumps and provide doctors with a way to detect, and possibly correct, the side effects of implants.
The SMART-PIV group
The group, which started its project in June 2002, is looking for
another €1.5 million to take its test system to commercialisation over
the next two years, says project coordinator Fabrizio Lagasco. That
money is being sought from the European Union's Seventh Framework
Programme or private sources. Each of the partners will share the
project's intellectual property equally.
The eight partners are:
- D'Appolonia, which is acting as coordinator for the project, Genova, Italy
- LaVision GmbH, Germany
- The University of Rome La Sapienza's Department of Mechanics and Aeronautics, Italy
- The Computing System Laboratory at the Institute of Communication and Computer Systems, Greece
- The Istituto Superiore di Sanita's Laboratory of Biomedical Engineering in Rome, Italy
- Berlin Heart AG, Germany
- RWTH/Aachen University of Technology, Germany
- Infobyte SpA, Italy
The scientists say the system fills a gap in the heart device sector that has limited the efficiency of implants. Ultrasound scans allow doctors to see potential problems with the natural heart and circulatory system, but they cannot provide a detailed analysis of the problems related to blood flow when it is modified by an artificial implanted device. Complications are widespread in patients who receive implants either as a long-term solution or interim treatment while awaiting a heart for transplantation.
At the core of the SMART-PIV system is miniaturised optical sensor technology that uses ultra-thin laser light sheets to capture images of the fluid dynamics of blood flowing through implanted devices. The system can then perform a numerical analysis on the images using a parallel computing subsystem to allow implant device designers or doctors to detect potential problems with the blood flow, such as high velocity gradients that can damage blood cells or low velocity that could lead to blood clots.
Test results in vitro show that the computing analysis can be completed in less than a day in 80 percent of cases, and in less than two days in all cases. The researchers now want to develop and evaluate it further in trials with a medical device manufacturer to move towards a commercial product. the group still needs two years to complete validation, upgrade software and imaging processing, and improve the graphical user interface of its technology, says Lagasco.
Lagasco says the consortium is in talks with Sorin Biomedica Cardio, a producer of heart valves, and with an Italian company looking to optimise the design of ventricular-assist devices (VADs) for heart patients.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
